Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503387-16-00

Acronym

SGN35-027

Enrollment

Registered

2023-10-10

Start date

2021-07-13

Completion date

2024-08-23

Last updated

2024-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Classical Hodgkin Lymphoma

Brief summary

CR rate at EOT

Detailed description

Incidence, severity, seriousness, and relatedness of AEs; incidence and severity of lab abnormalities, Estimate the ORR, DOR, DOCR, EFS, PFS

Interventions

DRUGDacarbazine Lipomed 500 mg powder for solution for infusion

DRUGDOXORUBICINE ACCORD 2 mg/ml

DRUGsolution pour perfusion

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
CR rate at EOT	—

Secondary

Measure	Time frame
Incidence, severity, seriousness, and relatedness of AEs; incidence and severity of lab abnormalities, Estimate the ORR, DOR, DOCR, EFS, PFS	—

Countries

Czechia, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026